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Abstract
Background—Cardiac rehabilitation (CR) is the standard of care for patients with coronary 
heart disease (CHD). Despite considerable epidemiologic evidence that high stress is associated 
with worse health outcomes, stress management training (SMT) is not included routinely as a 
component of CR.
Methods and Results—151 outpatients with CHD aged 36 to 84 years were randomized to 12-
weeks of comprehensive CR or comprehensive CR combined with SMT (CR+SMT), with 
assessments of stress and CHD biomarkers obtained before and after treatment. A matched sample 
of CR-eligible patients who did not receive CR comprised a No-CR comparison group. All 
participants were followed for up to 5.3 years (median = 3.2 years) for clinical events. Patients 
randomized to CR+SMT exhibited greater reductions in composite stress levels compared with 
those randomized to CR alone (P = 0.022), an effect that was driven primarily by improvements in 
anxiety, distress, and perceived stress. Both CR groups achieved significant, and comparable, 
improvements in CHD biomarkers. Participants in the CR+SMT group exhibited lower rates of 
clinical events compared with CR alone (18% vs. 33%, HR = 0.49 [0.25, 0.95], P = 0.035) and 
both CR groups had lower event rates compared to the No-CR group (47%, HR = 0.44 [0.27, 
0.71], P < .001).
Conclusions—CR enhanced by SMT produced significant reductions in stress and greater 
improvements in medical outcomes compared with standard CR. Our findings indicate that SMT 
may provide incremental benefit when combined with comprehensive CR and suggest that SMT 
should be incorporated routinely into CR.
Clinical Trial Registration Information—www.Clinicaltrials.gov. Identifier: NCT00981253.
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INTRODUCTION
Cardiac Rehabilitation (CR) is integral to the optimal medical care of patients with coronary 
heart disease (CHD).1, 2 Physical exercise, medical management of elevated blood pressure 
and lipids, nutritional counseling, and smoking cessation are core components of CR in this 
country. Although no single study has demonstrated definitively that exercise improves 
clinical outcomes in CHD patients, a recent meta-analysis concluded that CR reduces 
cardiovascular (CV) mortality and hospitalizations and improves quality of life.3
Stress management training (SMT) is not routinely included as a component of CR 
programs, despite mounting epidemiological evidence that elevated levels of stress are 
associated with greater risk of death and non-fatal cardiac events.4–6 The fact that SMT is 
not offered may be due to inconsistencies in the literature on the stress and CHD 
relationship, a lack of consensus regarding how stress is defined and measured, uncertainty 
about what approach is most effective, and limited support for the effectiveness of SMT in 
reducing stress and in improving clinical outcomes in CHD patients.7 We previously found 
that CHD patients with mental stress-induced myocardial ischemia receiving either SMT or 
exercise training had better clinical outcomes compared to usual care controls8 and that 
SMT and exercise each produced comparable improvements in psychological functioning as 
well as greater improvements in CHD biomarkers compared to usual care controls. 9 While 
these findings are encouraging, the added value of combining SMT with exercise training 
was not assessed. ‘Stand alone’ SMT interventions also may have limited real-world 
relevance, since such treatments are often not available in traditional disease-management 
programs.
The present study was designed to evaluate the potential incremental benefit of SMT when 
combined with comprehensive CR on a composite measure of psychological stress and CHD 
biomarkers of risk. In addition, we examined the impact of CR, alone and enhanced with 
SMT, compared to a non-randomized, matched comparison group of CR-eligible patients 
who elected not to participate in CR, on adverse clinical events over a follow-up period of up 
to 5.3 years.
METHODS
Eligibility and Trial Overview
ENHANcing Cardiac rEhabilitation with stress management training in patients with heart 
Disease (ENHANCED) was an efficacy trial examining the effects of SMT, when added to 
comprehensive CR, on self-reported stress, CHD biomarkers, and clinical outcomes. 
Participants underwent baseline measurement of stress, traditional CHD risk factors, and 
CHD biomarkers, and were randomly assigned to either comprehensive CR or 
comprehensive CR enhanced by SMT (CR+SMT). Participants were re-assessed at the 
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completion of the 12-week program and were followed for clinical events for a median of 
3.2 years (range 0.1 to 5.3 years). Assessors were blinded to patients’ treatment group 
assignment at the time of post-treatment assessments and endpoints were adjudicated 
without knowledge of patients’ treatment. The primary endpoint was a composite 
psychometric measure of stress. Secondary outcomes included CHD biomarkers and adverse 
cardiovascular events. A non-random sample of CR-eligible CHD patients formed a 
comparison group for the purpose of determining the event rates for patients with similar 
demographic and clinical characteristics who elected not to participate in CR.
This study was supported by grant HL093374 from the National Heart, Lung, and Blood 
Institute; the sponsor had no involvement in the design of the study; the collection, analysis, 
and interpretation of the data; or in the decision to approve publication of the finished 
manuscript.
Participants
Outpatients with stable CHD were referred for CR by their personal physicians and 
underwent medical screening examinations to confirm eligibility. Indications for CR 
included recent acute coronary syndrome, stable angina with angiographic evidence of 
coronary disease, and recent coronary revascularization (coronary artery bypass graft 
surgery or percutaneous coronary intervention). Exclusion criteria including surgery 
primarily for valve replacement or repair, heart transplant, left ventricular ejection fraction 
(LVEF) < 30%, and unrevascularized left main stenosis > 50%. The protocol was approved 
by the respective Institutional Review Boards at Duke University and the University of 
North Carolina and written informed consent was obtained from all participants. The first 
patient was randomized on April 6, 2010 and the last date for medical event adjudication 
was July 15, 2015.
Assessment procedures
Psychological Stress—A global ‘stress’ measure was the primary outcome, combining 
the following components using a mean rank constructed separately for each measure at 
baseline and following treatment:10
Beck Depression Inventory II (BDI-II)11: The 21-item BDI-II is a widely used measure of 
depression with scores ranging from 0 to 63, with higher scores suggesting greater 
depressive symptoms; scores ≥ 14 are suggestive of clinically significant depressive 
symptoms.
State-Trait Anxiety Inventory (STAI)12: The 20-item STAI was used to assess levels of state 
anxiety with scores ranging from 20 to 80; scores ≥ 40 suggest clinically significant anxiety 
in medical patients.13
Patient-Reported Outcomes Measurement Information System (PROMIS) Anger14: The 8-
item PROMIS Anger scale assesses several dimensions of anger with scores ranging from 8 
to 40 with higher scores indicating greater anger.
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General Health Questionnaire (GHQ)15: The GHQ is a 12-item measure of general distress, 
with scores ranging from 0 to 36 and higher scores indicating greater emotional distress.
Perceived Stress Scale (PSS)16: The 10-item PSS assesses general distress and perceived 
ability to adequately cope with current life stressors with scores ranging from 0 to 40; higher 
scores indicate greater perceived stress.
Exercise Tolerance and Physical Activity—Exercise Treadmill Testing. Patients 
exercised to exhaustion or other standard endpoints under continuous electrocardiographic 
monitoring using a ramped Bruce protocol.17
Accelerometry. Physical activity (PA) during daily life was quantified by recording the 
number of steps on two successive days using the Kentz Lifecorder Plus accelerometer 
NL-2160 (LC; Suzuken Co. Ltd., Nagoya Japan).
Leisure-time Physical Activity. Participants completed the Godin Leisure-Time Exercise 
Questionnaire18 in which they indicated the number of times they engaged in mild, 
moderate, and strenuous exercise for more than 15 minutes.
Blood Lipids—Lipids were measured enzymatically from fasting blood samples (LabCorp 
Inc, Burlington, NC).
CHD Biomarkers of Inflammation and Autonomic function—High sensitivity C-
Reactive Protein (hs-CRP) was quantified by ELISA. Values > 10 mg/L were truncated at 10 
in order to account for acute inflammatory processes that may haveskewed the distribution 
of this blood marker.
Heart Rate Variability (HRV) and Baroreflex Sensitivity (BRS) were obtained from beat-to-
beat heart rate (HR) and BP recorded from patients in the supine position using a Nexfin 
non-invasive BP monitor (Nexfin Model 1, BMEYE B.V., Amsterdam, the Netherlands).19 
HRV was assessed from R-R interval changes elicited during a 100 second controlled 
breathing task (HRV-DB) and during five minutes of normal relaxed breathing by estimating 
power spectra using the Welch algorithm.20 BRS also was estimated during this five-minute 
resting condition using cross-spectral analysis to estimate the magnitude of the transfer 
function relating R-R interval oscillations to systolic BP oscillations across the 0.07 to 
0.1299 Hz, or low frequency band.
Medical Endpoints—Patients documented all medical encounters annually up to five 
years following enrollment. Medical records were reviewed and events, categorized based on 
ACC/AHA criteria,21 were adjudicated by a physician assistant and a study cardiologist 
blinded to treatment condition. The following medical events were included: all-cause 
mortality, fatal and non-fatal myocardial infarction, coronary or peripheral artery 
revascularization, stroke/transient ischemic attack (TIA), and unstable angina requiring 
hospitalization.
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Interventions
Patients were randomized either to comprehensive CR-alone or CR+SMT. All patients were 
followed medically by their local cardiologists or primary care physicians, who were blinded 
to treatment condition and who managed any episodes of escalating symptoms or evidence 
of disease progression.
Comprehensive Cardiac Rehabilitation
Patients participated in CR at Duke University’s Center for Living (N=113) and the 
University of North Carolina’s Wellness Center in Chapel Hill (N=38). Comprehensive CR 
programs are similar throughout the state of North Carolina; patients engage in aerobic 
exercise three times a week for 35 minutes at a level of 70-85% of their HR reserve as 
determined at the time of their initial exercise treadmill test. Patients also received education 
about CHD, nutritional counselling based on American Heart Association guidelines, and 
two classes devoted to the role of stress in CHD.
SMT-enhanced Cardiac Rehabilitation (CR+SMT)
Patients in CR+SMT received the identical comprehensive CR intervention plus SMT. SMT 
was adapted from our previous work,8, 9 which combined education, group support, and 
cognitive-behavior therapy. The intervention was delivered in 12 weekly 1.5- hour sessions 
in groups of 4–8 participants. The SMT intervention is based upon a cognitive-behavioral 
model in which stress is conceptualized as an imbalance between high demands (often 
environmental, but also can be self-imposed) and more limited coping resources. The 
intervention, therefore, is directed at reducing demands and increasing coping abilities. The 
initial sessions are designed to establish rapport, promote group cohesion and social support, 
and provide a scientific basis for the importance of stress as a risk factor for adverse CV 
events. Strategies for reducing demands are presented including prioritizing, time 
management, establishing personal values, and avoidance of stress-producing situations. 
Subsequent sessions focus on modifying responses to situations that cannot be readily 
changed. Several sessions are devoted to training in progressive muscle relaxation 
techniques and the use of visual imagery to reduce stress. Emphasis is placed on the 
importance of cognitive appraisals in affecting stress responses, with recognition of 
irrational beliefs and cognitive distortions such as overgeneralization, catastrophizing, and 
all-or-nothing thinking. Later sessions focus on the importance of effective communication, 
including topics of assertiveness and anger management. Instruction in problem solving 
strategies is also provided in which participants are encouraged to apply the skills that they 
have learned to address everyday problems. Methods included brief lectures, group 
discussion, role playing, as well as instruction in specific behavioral skills, and weekly 
‘homework’ assignments.
Non-Randomized, No-Cardiac Rehabilitation Comparison Group (No-CR)
To estimate the impact of CR--with and without SMT-- on clinical outcomes, we collected 
medical event data for comparison with individuals who were referred to CR during the 
same time period as the CR-alone and CR+SMT participants, but who elected not to 
participate. Eligible patients were stratified based on age, gender, history of MI, and date of 
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referral. A total of 886 patients whose geographical location would have enabled them to 
participate in CR at Duke or UNC through CR referral records were identified from which 
75 were randomly selected, within strata by research personnel blinded to patients’ medical 
outcome data. Patients found to have enrolled in CR elsewhere also were excluded, although 
participation in self-initiated physical activity or stress reduction (e.g., psychotherapy) was 
permitted.
Statistical analysis
Treatment effects were evaluated using general linear models adjusting for baseline through 
SAS 9.2 (PROC GLM, SAS Institute, Cary, NC). For our primary analysis of change in 
‘stress’, a pre-planned rank-based global measure of stress was created using the BDI-II, 
GHQ, STAI, PROMIS Anger, and PSS scores. In this approach, the global measure was 
created by ranking each participant on each individual ‘stress’ measure at baseline and 
following treatment.10 A mean rank score was created by averaging across all ‘stress’ 
measures at pre-treatment and at post-treatment. Treatment effects were analyzed following 
the intention-to-treat (ITT) principle, with post-treatment missing data (< 5%) managed 
using multiple imputation methods available in SAS (PROC MI). We first examined changes 
in our global ‘stress’ outcome and, if significant, explored changes in individual components 
of the stress composite in a secondary, explanatory step.22 Our primary interest is not so 
much to identify which component is important, but rather to assess the effectiveness of 
treatment on a single, global measure of stress based on the elements comprising the ‘stress’ 
construct. We did not correct for multiple components because, as noted by Tandon,23 the 
Bonferroni correction fails to make efficient use of the collective data, especially when one 
expects several measures (e.g., stress, anger, depression, anxiety) to behave similarly and 
there is no a priori reason to believe that one of these measures would be more significant 
than another. Analyses of treatment changes in CHD biomarkers, lipids, and aerobic fitness / 
physical activity were conducted using the post-treatment value as the outcome variable, 
controlling for the respective pre-treatment level, with group assignment as the predictor of 
interest. In these analyses, a Bonferonni correction was applied to adjust for multiple 
comparisons separately within each outcome domain (i.e., CHD biomarkers, lipids, and 
aerobic fitness/physical activity).
For analysis of clinical events, we evaluated the effects of treatment using Cox proportional 
hazards model (PROC PHREG), with dummy coding constructed to compare the CR, CR
+SMT, and No-CR groups. In order to account for potential treatment differences in 
important medical predictors of clinical events, we controlled for age, heart failure, and 
treatment site in our models. Within our analyses of clinical event models the first event 
following randomization was coded as the event and those participants with no events or 
who dropped out were censored at the time of last contact. We also examined the impact of 
treatment on clinical events among CR+SMT and CR-alone participants compared to the 
No-CR group. We evaluated the extent to which models met assumptions, including 
additivity, linearity, proportional hazards, and distribution of residuals. A priori power 
estimates suggested that we would have 80% power to detect a 0.47-SD difference in the 
stress composite between the CR+SMT and CR-alone groups.
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RESULTS
Participant Flow
Figure 1 displays the flow of participants during the trial. Of the 577 individuals who were 
considered for CR, 164 met initial inclusion criteria and 151 were randomized: 75 to 
comprehensive cardiac rehabilitation (CR) and 76 to comprehensive cardiac rehabilitation 
plus SMT (CR+SMT).
Medical outcome data also were obtained for 75 individuals who were referred to CR but, 
for a variety of reasons (e.g., inconvenient, too busy, preferred to exercise on their own, not 
interested, etc.), elected not to participate in CR (No-CR).
Participant Characteristics
Demographic, background, and medical characteristics of the CR groups and No-CR 
patients are shown in Table 1. The treatment groups were similar on background clinical and 
demographic characteristics and also were similar to the No-CR comparison group.
Treatment Adherence
Exercise attendance was similar for both CR groups. Participants in CR-alone and CR+SMT 
each completed a mean of 33 out of a possible 36 exercise sessions (92% attendance). 
Attendance at SMT classes was excellent, with participants attending a median of 11 out of 
12 sessions. Six participants (4%) did not complete the treatment protocol: 3 from CR and 3 
from CR+SMT.
We used a modified version of the Morisky Adherence Scale 24 to assess medication 
adherence before and following the 12-week CR program with scores ranging from 0 to 7. 
Participants in CR-alone and CR+SMT were very adherent upon study entry: 95% indicated 
that they never or rarely missed taking their heart medications. Adherence was maintained 
over the 12 weeks and there was no difference in adherence between the two groups 
following treatment (CR+SMT = 0.30, CR-alone = 0.36; P = 0.52).
Effects of Treatment on Stress
Time and treatment changes for the stress measures are presented in Table 2, adjusted for the 
pretreatment level of each outcome. Both CR groups showed reductions on each stress 
component following treatment (P’s ≤ .001). A treatment group main effect was observed 
for the global Stress score in which the CR+SMT group showed greater reductions 
compared to CR-alone (P = 0.022). In secondary, explanatory analyses, we found that the 
CR+SMT group showed greater improvements in anxiety (STAI; P = 0.025) and distress 
(GHQ; P = 0.049), and tended to show greater reductions in perceived stress (PSS; P = 
0.063) compared with CR-alone. We note that univariate analyses of the stress components 
were not corrected, and serve as a guide to interpretation of the global test results. Of note, 
34 individuals exhibited clinically elevated levels of depression prior to treatment (i.e., BDI-
II ≥ 14) and 48 individuals reported clinically significant levels of anxiety (STAI ≥ 40). In 
supplementary analyses among this depressed subgroup, individuals in the CR+SMT group 
exhibited 14.0-point reduction (9.2, 18.8) on the BDI-II, compared with reductions of 7.8 
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(2.7, 12.9) points in the CR group (P = 0.07). Individuals with high anxiety in CR + SMT 
reported a 14.2-point reduction (9.6, 18.8) compared to a 9.8 (5.4, 14.2) reduction in CR 
alone (P = 0.18).
CHD Biomarkers, Lipids, and Exercise Capacity/Physical Activity
CR, alone and combined with SMT, was associated with significant improvements in CHD 
biomarkers, lipids, exercise capacity and physical activity during daily life. However, there 
were no treatment group differences on any of the measures (Table 3).
Comparison of Clinical Events in CR-alone and CR+SMT
Thirty-nine participants (26%) experienced a clinical event over a follow up period of up to 
5.3 years (median 3.2.; [IQR=1.9] years; Table 4). Time-to-event models demonstrated that 
participants randomized to CR+SMT experienced a lower event rate (18%) compared with 
individuals randomized to CR (33%; HR = 0.47 [0.24, 0.91], P = 0.03). The estimated 
optimism for model fit was modest (17%), suggesting minimal bias from overfitting.
Comparison of Clinical Events in CR Groups and Matched No-CR Controls
In order to assess the impact of CR on medical outcomes, we compared patients randomized 
to CR-alone and CR+SMT to a randomly selected sample of patients referred to CR but who 
elected not to participate; the comparison group was matched on age, indication for referral 
to CR, and time of referral. The follow-up interval was identical for CR and no-CR controls. 
We observed 35 clinical events in the No-CR group (47%), compared to 39 in the CR groups 
(26%; HR = 0.35 [0.22, 0.56], P < .001) (Figure 2).
Mediators of CR and Medical Events
We also examined whether reductions in stress levels mediated the relationship of CR on 
clinical events. Greater reductions in stress were associated with a lower rate of clinical 
events (HR = 0.58 [0.34, 0.99], P = 0.048). Controlling for reductions in stress attenuated the 
relationship between treatment group and clinical events (HR = 0.59 [0.31, 1.14], P = 0.11), 
while the relationship between stress and clinical events became marginally significant (HR 
= 0.60 [0.35, 1.02], P = 0.059), suggesting that reduced stress partially mediated the effects 
of treatment group on clinical outcomes.
DISCUSSION
Although there is substantial epidemiologic evidence that high levels of stress are associated 
with worse medical outcomes,4–6 there is considerably less evidence that interventions 
designed to reduce stress improve those outcomes.25 In the present trial, stress management, 
when added to comprehensive CR, resulted in greater reductions in patient-reported stress 
compared to CR alone. Furthermore, reductions in stress were associated with reduced risk 
of adverse clinical events, with almost a 50% reduction in clinical events compared to CR 
without SMT.
Participants in both CR and CR+SMT achieved improvements in blood lipids, heart rate 
variability, inflammation, exercise tolerance and self-reported leisure time physical activity. 
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In a secondary analysis, we also noted that CR was associated with better clinical outcomes 
relative to a No-CR comparison group. The overall event rates were higher for patients who 
elected not to engage in CR compared to CR alone or CR+SMT. These findings contrast 
with results from the recent RAMIT study,26 which found that comprehensive CR had no 
effect on mortality, cardiac or psychological morbidity, and concluded that the evidence for 
the value of CR was “weak.” Important differences in how CR is practiced in England and 
the United States may explain the discrepant results. In the British study, CR was performed 
weekly for only 6–10 weeks, while in the US, CR is more intensive. In the ENHANCED 
trial, patients engaged in exercise three times per week for 12 weeks, and participated in 
nutrition and stress classes; patients randomized to the CR+SMT group also received an 
additional 1.5 hrs per week of group SMT. While patients in CR+SMT reported reduced 
symptoms of anxiety, depression, and stress, the stress reduction program for the RAMIT 
trial did not reduce patients’ stress levels, which could account for the differences in clinical 
outcomes.
Several other large RCTs reported no benefit of SMT compared to usual care controls in 
reducing stress and improving clinical outcomes. Jones and West27 randomized 2,328 post-
MI patients to 7 weekly sessions of SMT or usual care and followed them for 12 months. 
After six months, the prevalence rates of clinical anxiety and depression remained high and 
there were no group differences in levels of anxiety or depression following treatment. 
Moreover, there was no difference between the groups in the incidence of MI, 
cerebrovascular accident, heart failure, or revascularizations. Frasure-Smith and colleagues28 
randomized 1,376 post-MI patients to a stress management intervention delivered over the 
telephone or to usual care. Following treatment, there were no group differences in anxiety 
or depression and there also was no difference in clinical outcomes. The ENRICHD trial 29 
examined the benefits of a cognitive-behavioral intervention in 2400 post-MI patients who 
were depressed or who reported low social support. Results showed a modest, 2-point 
difference in BDI scores in the intervention group compared to usual care, and there were no 
differences in the combined endpoint of all-cause mortality and non-fatal reinfarction. These 
aforementioned studies also provided SMT as a sole intervention, without exercise or other 
elements of comprehensive CR. Thus, not all interventions designed to reduce stress are 
successful, and the failure to reduce stress may provide one explanation for the failure to 
observe improved medical outcomes.
The ENHANCED trial provided SMT to all patients randomized to the CR+SMT 
intervention, regardless of their baseline levels of stress and did not specifically target 
patients in acute distress or with significant psychopathology. Few RCTs include only 
patients meeting a clinical threshold for psychological symptoms or psychiatric pathology, 
and in studies with and without patients with diagnosed psychopathology the results are 
often not reported separately.30 Some meta analyses suggest that patients with greater 
psychopathology at baseline show smaller reductions in depression with treatment compared 
with patients with less psychopathology.30 We found that patients with greater stress tended 
to exhibit larger improvements. For example, depressive symptoms were reduced in both CR 
and CR+SMT groups, which is not surprising given that depressive symptoms are reduced 
by CR,31 and that exercise has been shown to reduce depressive symptoms in patients with 
major depression,32 stable CHD33 and heart failure.34 Although failing to achieve statistical 
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significance, it is noteworthy that in our subset of patients with elevated depressive 
symptoms upon study entry, the addition of SMT to CR appeared to be especially beneficial. 
The CR+SMT group exhibited a 14-point reduction in BDI-II scores compared to an 8-point 
reduction with CR alone. A 6-point difference is considered clinically meaningful and is 
greater than the 2- to 3-point differences observed in placebo-controlled trials of 
antidepressant medications35–37 and in trials of psychotherapy in CHD patients.29
Limitations
Our sample was small and we observed few ‘hard’ endpoints (e.g., death and non-fatal MI). 
A larger sample would provide greater power to detect treatment group differences in 
specific stress components. Although the effect sizes were relatively modest, because 
comprehensive CR alone has been shown to produce significant improvements in quality of 
life,3 the incremental benefit of SMT to standard CR should not be underestimated In 
addition, analysis of clinical events offered promising evidence for the value of CR+SMT in 
improving clinical outcomes, which will need to be confirmed in larger trials. CR 
participants had better clinical outcomes compared to patients who elected not to engage in 
CR. Patients in the no-CR comparison group were matched on age, gender, and history of 
MI, did not differ on any measured clinical or demographic characteristic, and continued to 
exhibit significantly higher rates of clinical events in sensitivity analyses adjusted for age, 
gender, ejection fraction, and medical comorbidities. However, it is possible that patients in 
the non-random comparison group may have differed from the CR participants in ways that 
we did not measure, which may have contributed to their higher rates of clinical events. We 
used a global measure of stress, combining scores from multiple instruments. Because there 
is no universally accepted single measure of stress, we selected well-validated instruments 
based upon epidemiologic evidence that distress,15, 38 depression,39–43 anxiety,44–46 and 
anger 47, 48 -- generally subsumed under the term “stress”-- are associated with increased 
risk for adverse outcomes in CHD patients. Composite measures of stress have been used in 
other studies,6 but there is still no ‘gold standard’ for measuring stress and our global 
measure combines scores from well-validated instruments, each with excellent psychometric 
properties. Adherence to the program was excellent with few dropouts. Research volunteers 
may have been especially motivated to participate in the program, which may limit the 
generalizability of our findings.
Conclusion
Patients randomized to CR enhanced by stress management had greater reductions in stress 
and had better clinical outcomes compared to those patients randomized to CR alone. In the 
same way that exercise training does not target only those patients with low levels of 
physical fitness, the present findings indicate that SMT could be beneficial for all cardiac 
patients and suggest that SMT should be incorporated into comprehensive CR. A multi-site 
effectiveness trial will be needed to confirm the applicability of these findings to the larger 
CR population.
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Clinical Perspectives
Cardiac rehabilitation (CR) represents the standard of care for patients with coronary 
heart disease (CHD). Despite considerable epidemiologic evidence that high levels of 
stress are associated with worse prognosis, there is limited evidence that reducing stress 
improves clinical outcomes. ENHANCED was a randomized clinical trial in which 
patients referred to CR completed a psychometric ‘stress’ battery and underwent 
evaluation of CHD biomarkers including measures of endothelial dysfunction, heart rate 
variability, baroreflex sensitivity, and inflammation before and after a 12-week treatment 
program of comprehensive CR alone (N= 75) or comprehensive CR enhanced by stress 
management training (SMT)(N=76). SMT consisted of 12 weekly, 1.5 hour sessions that 
provided education, group support, and instruction in methods for coping more 
effectively with stress (e.g., time management, progressive muscle relaxation training, 
cognitive restructuring, communication skills). A non-random sample of CR-eligible 
patients who declined to engage in CR formed a no-CR comparison group. Results 
showed that while both CR groups reported less stress, CR enhanced by SMT achieved 
greater reductions in stress compared to CR-alone. Compared to the matched no-CR 
comparison group, both CR groups had fewer clinical events (all-cause mortality, fatal 
and non-fatal myocardial infarction, coronary or peripheral artery revascularization, 
stroke/transient ischemic attack (TIA), and unstable angina requiring hospitalization). 
Moreover, combining stress management training with CR (i.e., CR+SMT) resulted in 
better clinical outcomes compared to CR-alone. These findings confirm the value of CR 
in reducing the risk for adverse clinical events. Furthermore, SMT provided incremental 
value to standard CR by further reducing stress and improving clinical outcomes. 
Including SMT as a routine component of standard CR, regardless of patients’ reported 
levels of stress, should be encouraged.
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Figure 1. 
Participant flow in the ENHANCED (Enhancing Standard Cardiac Rehabilitation with 
Stress Management Training in Patients with Coronary Heart Disease) clinical trial. CR = 
Cardiac Rehabilitation; CR+SMT = Cardiac Rehabilitation Enhanced with Stress 
Management Training; ITT = intention-to-treat.
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Figure 2. 
Cumulative time-to-event curves for clinical events in the CR+SMT, CR-alone, and No-CR 
groups. Clinical events included all-cause mortality, myocardial infarction, cardiac or 
peripheral vascular intervention, stroke/TIA, or unstable angina requiring hospitalization. 
Participants in the CR+SMT were at significantly lower risk of clinical events compared 
with the CR-alone group (HR= 0.47 [0.24, 0.91], P = 0.025). Both CR groups had lower 
event rates compared with a non-randomized, matched No-CR control group (HR = 0.35 
[0.22, 0.56], P < .001). Number at risk represents participants with follow-up data for 
clinical events who had not yet had an event at years 0, 2, and 4.
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Table 1
Background characteristics of the ENHANCED sample.
Variable CR + SMT
(n = 76)
CR
(n = 75)
No-CR
(n = 75)
Background and Demographics (n [%])
Age, mean (SD) y 61.8 (10.8) 60.4 (10.6) 60.9 (9.1)
Female 31 (41%) 24 (32%) 28 (37%)
White 58 (76%) 51 (68%) 50 (67%)
Married or Co-habitating 50 (66%) 49 (65%) 41 (55%)
Employed Full-time 29 (38%) 28 (37%) 34 (45%)
Current or Former Smoker 38 (50%) 41 (55%) 49 (65%)
Body Mass Index, mean (SD) kg / m2 30.2 (5.9) 30.8 (5.2) 30.3 (5.8)
Medical History (n [%])
Hypertension 58 (76%) 60 (80%) 58 (77%)
Hyperlipidemia 61 (80%) 57 (76%) 64 (85%)
Diabetes 25 (33%) 31 (41%) 28 (37%)
Myocardial Infarction History† 38 (50%) 43 (57%) 41 (55%)
Coronary Artery Bypass Graft History† 21 (28%) 17 (23%) 22 (29%)
Heart Failure 5 (7%) 3 (4%) 5 (7%)
Chronic Kidney Disease 2 (3%) 3 (4%) 3 (4%)
Charlson Comorbidity Index, mean (SD) 1.2 (1.1) 1.3 (1.0) 1.3 (1.1)
LVEF, mean (SD) % 55.1 (9.6) 54.3 (7.4) 54.3 (7.0)
Indication for Cardiac Rehabilitation
   Coronary Artery Bypass Grafting (CABG) 19 (25%) 10 (13%) 19 (25%)
   Percutaneous Coronary Intervention (PCI)* 29 (38%) 23 (31%) 11 (15%)
   Myocardial Infarction 3 (4%) 8 (11%) 11 (15%)
   Myocardial Infarction + CABG 2 (3%) 2 (3%) 4 (5%)
   Myocardial Infarction + PCI 20 (37%) 26 (35%) 20 (27%)
   Angina 3 (4%) 6 (8%) 10 (13%)
ACE-Inhibitor or Angiotensin Receptor Blocker 47 (62%) 55 (73%) 46 (61%)
Beta Blocker 66 (87%) 67 (89%) 66 (88%)
Calcium Channel Blocker 10 (13%) 17 (23%) 13 (17%)
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Variable CR + SMT
(n = 76)
CR
(n = 75)
No-CR
(n = 75)
Diuretic 22 (29%) 23 (31%) 24 (32%)
Other Blood Pressure Medication 2 (3%) 5 (7%) 2 (3%)
Diabetes Medication 22 (29%) 25 (33%) 32 (43%)
Nitrates 42 (55%) 43 (57%) 43 (57%)
Aspirin 72 (95 %) 72 (96 %) 73 (97 %)
Other Anti-Platelet Medication 56 (74%) 53 (71%) 45 (60%)
Psychotropic Medication 26 (34%) 26 (35%) 24 (32%)
Statin 66 (87%) 66 (88%) 65 (87%)
Lipids and Blood Pressure (mean, [SD])
Total Cholesterol, mg/dL 175.4 (46.4) 161.7 (42.0) -------------------
LDL Cholesterol mg/dL* 109.6 (42.5) 94.1 (40.6) -------------------
HDL Cholesterol, mg/dL 40.5 (11.9) 41.6 (11.9) -------------------
Serum Triglycerides, mg/dL 132.8 (74.4) 150.1 (88.4) -------------------
Systolic Blood Pressure, mm Hg 113.5 (15.0) 116.6 (16.7) -------------------
Diastolic Blood Pressure, mm Hg 61.9 (7.6) 62.9 (9.0) -------------------
Aerobic Fitness and Physical Activity (mean [SD])
Exercise Treadmill Test Duration (min) 7.7 (2.5) 7.3 (2.4) -------------------
Metabolic Equivalents (METs) 8.6 (2.4) 8.2 (2.6) -------------------
Accelerometry Steps 10,774 (5783) 10,840 (6312) -------------------
Accelerometry Light Activity (min) 29.9 (14.1) 31.5 (16.8) -------------------
Accelerometry Moderate Activity (min) 91.6 (53.2) 91.5 (59.1) -------------------
Accelerometry Total Activity (min) 121.7 (63.1) 123.4 (70.1) -------------------
Leisure-Time Physical Activity (min) 22.4 (19.7) 18.5 (22.5) -------------------
Coronary Heart Disease Biomarkers (mean [SD])
HRV-DB (msec) 149 (118) 171 (123) -------------------
Low Frequency HRV (ln msec2) 4.0 (1.1) 4.2 (1.4) -------------------
High Frequency HRV (ln msec2) 4.9 (0.9) 5.2 (1.2) -------------------
Baroreflex Sensitivity (msec/mmHg) 6.1 (3.7) 7.0 (5.1) -------------------
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Variable CR + SMT
(n = 76)
CR
(n = 75)
No-CR
(n = 75)
hsCRP (mg/L) 2.6 (3.1) 2.7 (2.8) -------------------
Composite Stress Measures (mean [SD])
Beck Depression Inventory-II 8.1 (7.7) 9.0 (9.0) -------------------
Spielberger Anxiety Inventory-State 35.1 (11.8) 36.3 (11.8) -------------------
PROMIS Anger 16.1 (5.5) 16.2 (6.1) -------------------
General Health Questionnaire 12.6 (5.9) 12.3 (6.0) -------------------
Perceived Stress 15.3 (8.2) 15.4 (7.9) -------------------
*
P < .05 for treatment group differences; SD = standard deviation; LVEF = left ventricular ejection fraction; LDL = Low Density Lipoprotein; HDL 
= High Density Lipoprotein; HRV = Heart Rate Variability; HRV-DB = Heart Rate Variability during Deep Breathing; hsCRP = high sensitivity C-
Reactive Protein; PROMIS = Patient-Reported Outcomes Measurement Information System.
†
Includes previous medical history for event as well as current indication for referral to cardiac rehabilitation (i.e., recent event)
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Table 3
Treatment effects on CHD biomarkers, lipids, and physical activity after adjustment for the pretreatment level 
of each outcome. Values are presented as mean change scores from baseline (95% confidence intervals). P-
values are adjusted for multiplicity within each domain using a Bonferonni correction.
Variable CR + SMT
(n = 76)
CR
(n = 75)
Time
Effect
CR + SMT
vs. CR
Contrast
Lipids
Total Cholesterol, mg/dL −22.9 (−31.9, −14.0) −20.0 (−29.7, −10.2) <0.01 0.99
LDL Cholesterol, mg/dL −24.2 (−31.7, −16.8) −22.4 (−30.5, −14.3) <0.01 0.99
HDL Cholesterol, mg/dL    3.0 (1.2, 4.7)    2.7 (0.7, 4.6) <0.01 0.99
Triglycerides, mg/dL −7.4 (−21.2, 6.4) −11.2 (−26.6, 4.2) 0.22 0.99
CHD Biomarkers
hsCRP, mg/L   −0.9 (−1.4, −0.5)   −0.4 (−0.9, 0.0) <0.01 0.95
HRV-DB (msec) 13.1 (−8.0, 34.3) 26.0 (5.5, 46.5)   0.055 0.99
Low Frequency HRV, log-transformed 0.17 (−0.08, 0.41) 0.28 (0.04, 0.51)   0.075 0.99
High Frequency HRV, log-transformed 0.08 (−0.11, 0.27) 0.22 (0.03, 0.41)   0.17 0.99
Baroreflex Sensitivity, msec/mm Hg 0.47 (−0.39, 1.33) 0.93 (0.09, 1.77)   0.21 0.99
Aerobic Fitness and Physical Activity
Leisure-time Physical Activity 20.6 (15.6, 25.5) 15.9 (10.8, 21.0) <0.01 0.67
Exercise Treadmill Duration, min    1.2 (0.8, 1.7)    1.5 (1.1, 1.9) <0.01 0.99
Exercise Treadmill Metabolic Equivalents (METs)    1.5 (1.1, 1.8) 1.5 (1.2, 1.9) <0.01 0.99
Accelerometry Total Steps 1412 (213, 2610) 687 (−520, 1893) 0.092 0.99
Note: HDL = high density lipoprotein; HRV = heart rate variability; hsCRP = high sensitivity C-reactive protein; LDL = low density lipoprotein.
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